Innovent Biologics, Inc. (1801.HK)

HKD 36.2

(-0.82%)

Total Debt Summary of Innovent Biologics, Inc.

Innovent Biologics, Inc.'s latest annual total debt in 2023 was 3.62 Billion CNY , up 12.14% from previous year.
Innovent Biologics, Inc.'s latest quarterly total debt in 2023 FY was 3.62 Billion CNY , up 12.14% from previous quarter.
Innovent Biologics, Inc. reported annual total debt of 3.22 Billion CNY in 2022, up 29.3% from previous year.
Innovent Biologics, Inc. reported annual total debt of 2.49 Billion CNY in 2021, up 106.94% from previous year.
Innovent Biologics, Inc. reported quarterly total debt of 3.62 Billion CNY for 2023 Q4, up 0.7% from previous quarter.
Innovent Biologics, Inc. reported quarterly total debt of 3.62 Billion CNY for 2023 FY, up 12.14% from previous quarter.

Annual Total Debt Chart of Innovent Biologics, Inc. (2023 - 2016)

Historical Annual Total Debt of Innovent Biologics, Inc. (2023 - 2016)

Year	Total Debt	Total Debt Growth
2023	3.62 Billion CNY	12.14%
2022	3.22 Billion CNY	29.3%
2021	2.49 Billion CNY	106.94%
2020	1.2 Billion CNY	39.47%
2019	865.08 Million CNY	9.23%
2018	792 Million CNY	55.29%
2017	510 Million CNY	2.0%
2016	500 Million CNY	0.0%

Year	Total Debt	Total Debt Growth
2023 Q2	3.45 Billion CNY	0.79%
2023 Q4	3.62 Billion CNY	0.7%
2023 FY	3.62 Billion CNY	12.14%
2023 Q3	3.59 Billion CNY	4.14%
2023 Q1	3.42 Billion CNY	6.09%
2022 Q1	2.75 Billion CNY	10.14%
2022 FY	3.22 Billion CNY	29.3%
2022 Q3	3.2 Billion CNY	15.76%
2022 Q2	2.76 Billion CNY	0.58%
2022 Q4	3.22 Billion CNY	0.82%
2021 Q3	2.47 Billion CNY	33.32%
2021 FY	2.49 Billion CNY	106.94%
2021 Q1	1.84 Billion CNY	52.6%
2021 Q2	1.85 Billion CNY	0.81%
2021 Q4	2.49 Billion CNY	0.9%
2020 Q1	955.4 Million CNY	10.44%
2020 Q3	1.19 Billion CNY	22.61%
2020 Q2	970.85 Million CNY	1.62%
2020 Q4	1.2 Billion CNY	1.36%
2020 FY	1.2 Billion CNY	39.47%
2019 FY	865.08 Million CNY	9.23%
2019 Q4	865.08 Million CNY	1.83%
2019 Q3	849.53 Million CNY	3.14%
2019 Q2	823.68 Million CNY	0.86%
2019 Q1	816.61 Million CNY	3.11%
2018 Q1	4.24 Billion CNY	732.77%
2018 Q3	792 Million CNY	13.63%
2018 FY	792 Million CNY	55.29%
2018 Q4	792 Million CNY	0.0%
2018 Q2	697 Million CNY	-83.59%
2017 Q3	3.56 Billion CNY	0.0%
2017 Q1	- CNY	0.0%
2017 Q4	510 Million CNY	-85.68%
2017 FY	510 Million CNY	2.0%
2016 FY	500 Million CNY	0.0%

Peer Total Debt Comparison of Innovent Biologics, Inc.

Name	Total Debt	Total Debt Difference
Uni-Bio Science Group Limited	52.86 Million HKD	-6748.372%
CK Life Sciences Int'l., (Holdings) Inc.	5.93 Billion HKD	38.957%